$DRIO
DarioHealth Corp.

2024 Q1 Form 10-K Financial Statement

#000155837024004151 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $5.758M $3.616M $20.35M
YoY Change -18.51% -46.89% -26.41%
Cost Of Revenue $3.326M $3.484M $14.37M
YoY Change -14.67% -14.55% -20.18%
Gross Profit $2.432M $132.0K $5.984M
YoY Change -23.23% -95.17% -38.02%
Gross Profit Margin 42.24% 3.65% 29.4%
Selling, General & Admin $13.65M $10.15M $41.93M
YoY Change 31.06% 45.85% -10.45%
% of Gross Profit 561.06% 7690.15% 700.62%
Research & Development $6.642M $4.196M $20.25M
YoY Change 28.6% -12.25% 3.05%
% of Gross Profit 273.11% 3178.79% 338.37%
Depreciation & Amortization $110.0K $1.315M $4.985M
YoY Change 13.4% 5.2% 1300.28%
% of Gross Profit 4.52% 996.21% 83.31%
Operating Expenses $20.29M $14.35M $62.17M
YoY Change 30.25% 22.19% -6.46%
Operating Profit -$17.86M -$14.21M -$56.19M
YoY Change 43.9% 57.77% -1.09%
Interest Expense $9.606M $583.0K $2.365M
YoY Change -1759.07% -338.93% -2310.28%
% of Operating Profit
Other Income/Expense, Net $8.686M -$49.00K -$645.0K
YoY Change -2182.97% 104.17% -88.01%
Pretax Income -$9.169M -$14.22M -$59.36M
YoY Change -28.51% 12.74% -4.54%
Income Tax -$1.994M $64.00K $64.00K
% Of Pretax Income
Net Earnings -$7.175M -$15.51M -$63.51M
YoY Change -44.05% 20.37% 2.12%
Net Earnings / Revenue -124.61% -428.82% -312.06%
Basic Earnings Per Share $0.20 $1.93
Diluted Earnings Per Share $0.20 -$0.54 -$2.24
COMMON SHARES
Basic Shares Outstanding 29.44M 27.21M 28.37M
Diluted Shares Outstanding 34.44M 28.37M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.34M $37.09M $37.09M
YoY Change -18.42% -25.11% -25.11%
Cash & Equivalents $34.37M $36.80M $36.80M
Short-Term Investments $971.0K $292.0K $292.0K
Other Short-Term Assets $250.0K
YoY Change 4.6%
Inventory $4.916M $5.062M $5.062M
Prepaid Expenses
Receivables $7.885M $3.155M $3.155M
Other Receivables $4.370M $2.024M $2.024M
Total Short-Term Assets $52.51M $47.33M $47.33M
YoY Change -5.35% -27.77% -27.77%
LONG-TERM ASSETS
Property, Plant & Equipment $1.425M $1.866M $1.866M
YoY Change 86.27% 136.8% -6.42%
Goodwill $57.43M $41.64M
YoY Change 37.91% 0.0%
Intangibles $23.65M $5.404M
YoY Change 168.61% -45.5%
Long-Term Investments
YoY Change
Other Assets $144.0K $149.0K $149.0K
YoY Change -7.1% 27.35% 27.35%
Total Long-Term Assets $84.46M $49.06M $49.06M
YoY Change 60.77% -8.59% -8.59%
TOTAL ASSETS
Total Short-Term Assets $52.51M $47.33M $47.33M
Total Long-Term Assets $84.46M $49.06M $49.06M
Total Assets $137.0M $96.39M $96.39M
YoY Change 26.81% -19.13% -19.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.14M $7.431M $1.131M
YoY Change 42.45% -16.64% -51.29%
Accrued Expenses $920.0K $111.0K $6.411M
YoY Change 216.15% -94.92% -6.88%
Deferred Revenue $1.791M $997.0K
YoY Change 93.62% -24.47%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.954M $3.954M $3.954M
YoY Change -53.93% -55.19% -55.19%
Total Short-Term Liabilities $17.80M $12.49M $12.49M
YoY Change 1.05% -35.44% -35.44%
LONG-TERM LIABILITIES
Long-Term Debt $24.51M $24.59M $24.59M
YoY Change 46.36% 35.82% 35.82%
Other Long-Term Liabilities $52.00K $1.161M $1.161M
YoY Change 44.44% -33.16% -33.16%
Total Long-Term Liabilities $41.13M $25.75M $25.75M
YoY Change 123.99% 29.79% 29.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.80M $12.49M $12.49M
Total Long-Term Liabilities $41.13M $25.75M $25.75M
Total Liabilities $58.93M $38.25M $38.25M
YoY Change 63.79% -2.42% -2.42%
SHAREHOLDERS EQUITY
Retained Earnings -$358.6M -$349.4M
YoY Change 20.05% 22.22%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $78.03M $58.14M $58.14M
YoY Change
Total Liabilities & Shareholders Equity $137.0M $96.39M $96.39M
YoY Change 26.81% -19.13% -19.13%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$7.175M -$15.51M -$63.51M
YoY Change -44.05% 20.37% 2.12%
Depreciation, Depletion And Amortization $110.0K $1.315M $4.985M
YoY Change 13.4% 5.2% 1300.28%
Cash From Operating Activities -$13.11M -$7.339M -$30.38M
YoY Change 175.59% -7.58% -36.51%
INVESTING ACTIVITIES
Capital Expenditures $56.00K $84.00K $584.0K
YoY Change -24.32% 42.37% 32.13%
Acquisitions $8.796M
YoY Change
Other Investing Activities -$8.796M -$3.000K $37.00K
YoY Change 105.13%
Cash From Investing Activities -$8.852M -$87.00K -$547.0K
YoY Change 102.93% 47.46% -4.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $16.48M
YoY Change -143.2%
Debt Paid & Issued, Net $27.83M
YoY Change
Cash From Financing Activities 20.21M 3.000K 18.25M
YoY Change -1554.72% -98.87% -70.53%
NET CHANGE
Cash From Operating Activities -13.11M -7.339M -30.38M
Cash From Investing Activities -8.852M -87.00K -547.0K
Cash From Financing Activities 20.21M 3.000K 18.25M
Net Change In Cash -1.756M -7.423M -12.67M
YoY Change -83.29% -4.03% -193.72%
FREE CASH FLOW
Cash From Operating Activities -$13.11M -$7.339M -$30.38M
Capital Expenditures $56.00K $84.00K $584.0K
Free Cash Flow -$13.17M -$7.423M -$30.96M
YoY Change 172.53% -7.21% -35.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001533998
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3567
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
18959
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25724470
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27191849
CY2022Q4 drio Conversion Of Preferred Stock Share Holding Period
ConversionOfPreferredStockShareHoldingPeriod
P36M
CY2022Q4 drio Conversion Of Preferred Stock Share Holding Period
ConversionOfPreferredStockShareHoldingPeriod
P36M
CY2023Q1 drio Conversion Of Preferred Stock Share Holding Period
ConversionOfPreferredStockShareHoldingPeriod
P36M
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37704
CY2023 dei Entity Registrant Name
EntityRegistrantName
DARIOHEALTH CORP.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2973162
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
322 W. 57th St.
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10011
CY2023 dei City Area Code
CityAreaCode
972
CY2023 dei Local Phone Number
LocalPhoneNumber
4 770-6377
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
DRIO
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
98193532
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29442532
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
1281
CY2023 dei Auditor Name
AuditorName
KOST FORER GABBAY & KASIERER
CY2023 dei Auditor Location
AuditorLocation
Tel-Aviv, Israel
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36797000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49357000
CY2023Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
292000
CY2022Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
165000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3155000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6416000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5062000
CY2022Q4 us-gaap Inventory Net
InventoryNet
7956000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2024000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1630000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
47330000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
65524000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
6000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
6000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
967000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1206000
CY2023Q4 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
143000
CY2022Q4 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
111000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
899000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
788000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5404000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9916000
CY2023Q4 us-gaap Goodwill
Goodwill
41640000
CY2022Q4 us-gaap Goodwill
Goodwill
41640000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
49059000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
53667000
CY2023Q4 us-gaap Assets
Assets
96389000
CY2022Q4 us-gaap Assets
Assets
119191000
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1131000
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2322000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
997000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1320000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
111000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
293000
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6300000
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6592000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3954000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
8823000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12493000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19350000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
885000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
827000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24591000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
18105000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
240000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
910000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
36000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
25752000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
19842000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27191849
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25724470
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
18959
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3567
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
407502000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
365846000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349361000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-285850000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
58144000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
79999000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96389000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119191000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20352000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
27656000
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14368000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18001000
CY2023 us-gaap Gross Profit
GrossProfit
5984000
CY2022 us-gaap Gross Profit
GrossProfit
9655000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20248000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19649000
CY2023 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
23785000
CY2022 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
30323000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18140000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16493000
CY2023 us-gaap Operating Expenses
OperatingExpenses
62173000
CY2022 us-gaap Operating Expenses
OperatingExpenses
66465000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-56189000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-56810000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3174000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5379000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59363000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62189000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
64000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-59427000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62193000
CY2023 drio Deemed Dividend
DeemedDividend
-4084000
CY2022 drio Deemed Dividend
DeemedDividend
-1643000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63511000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63836000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.93
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.93
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.54
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.54
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28371979
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28371979
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23635038
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23635038
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
85549000
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
377000
CY2022 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
190000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3105000
CY2022 drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
38288000
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1186000
CY2022 drio Adjustment To Additional Paid In Capital Business Combination Contingent Consideration Liability Extinguishment
AdjustmentToAdditionalPaidInCapitalBusinessCombinationContingentConsiderationLiabilityExtinguishment
328000
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
134000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13303000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-62193000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
79999000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3516000
CY2023 drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
16482000
CY2023 drio Adjustments To Additional Paid In Capital Warrant Issued Related To Loan Agreement
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedToLoanAgreement
1389000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
16185000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-59427000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
58144000
CY2023 us-gaap Profit Loss
ProfitLoss
-59427000
CY2022 us-gaap Profit Loss
ProfitLoss
-62193000
CY2023 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
19701000
CY2022 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
16975000
CY2023 us-gaap Depreciation
Depreciation
473000
CY2022 us-gaap Depreciation
Depreciation
356000
CY2023 drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-239000
CY2022 drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
919000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4512000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4361000
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-3261000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
5106000
CY2023 drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
-426000
CY2022 drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
-3000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2894000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1728000
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1191000
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2787000
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-256000
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1314000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-323000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
125000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-124000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
833000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-497000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
528000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4052000
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
240000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30379000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47845000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
584000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
442000
CY2023 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
4996000
CY2023 us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
5033000
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
131000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-547000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-573000
CY2023 drio Proceeds From Issuance Of Common Stock Preferred Stock And Warrants
ProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants
1614000
CY2022 drio Proceeds From Issuance Of Common Stock Preferred Stock And Warrants
ProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants
38288000
CY2023 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
14868000
CY2023 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
29604000
CY2022 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
23786000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
27833000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
134000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18253000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61940000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12673000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
13522000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49470000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35948000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36797000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49470000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
4031000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1876000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
136000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1269000
CY2022 drio Business Combination Contingent Consideration Liability Extinguishment Amount
BusinessCombinationContingentConsiderationLiabilityExtinguishmentAmount
328000
CY2023 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349361000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30379000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;border:0;"><tr><td style="width:17.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Use of estimates:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 34.85pt;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 34.85pt;">These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements including other accounts receivable and prepaid expenses and other accounts payable and accrued expenses, and the reported amounts of revenue, cost of revenues and operational expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4 drio Short Term Restricted Bank Deposits Collateral For Rent
ShortTermRestrictedBankDepositsCollateralForRent
229000
CY2022Q4 drio Short Term Restricted Bank Deposits Collateral For Rent
ShortTermRestrictedBankDepositsCollateralForRent
113000
CY2023Q4 drio Short Term Restricted Bank Deposits Collateral For Credit Payment
ShortTermRestrictedBankDepositsCollateralForCreditPayment
63000
CY2022Q4 drio Short Term Restricted Bank Deposits Collateral For Credit Payment
ShortTermRestrictedBankDepositsCollateralForCreditPayment
52000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36797000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49357000
CY2022Q4 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
113000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36797000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49470000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
121000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
88000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<table style="border-collapse:collapse;border:0;"><tr><td style="width:17.85pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">m.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Concentrations of credit risk:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 34.85pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:0pt;"></span><span style="display:inline-block;width:0pt;"></span>Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents, short-term deposits, restricted deposits, and trade receivables. For cash and cash equivalents, the Company is exposed to credit risks in the event of default by the financial institutions to the extent that amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 34.85pt;">For trade receivables, the Company is exposed to credit risk in the event of non-payment by customers to the extent of the amounts recorded on the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 34.85pt;">As of December 31, 2023, the Company's major customer accounted for 66.5% of the Company's accounts receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 34.85pt;">For the year ended December 31, 2023 and December 31, 2022, the Company's major customer accounted for 29.9% and 39.8%, respectively, of the Company's revenue in the period.</p>
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 drio Percentage Of Monthly Deposits Behalf Of Insurance Companies
PercentageOfMonthlyDepositsBehalfOfInsuranceCompanies
0.0833
CY2023 us-gaap Severance Costs1
SeveranceCosts1
947000
CY2022 us-gaap Severance Costs1
SeveranceCosts1
1136000
CY2023 drio Defined Contribution Plan Maximum Annual Contributions Per Employee Amount Over Fifty Years Of Age
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmountOverFiftyYearsOfAge
30000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1536000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
908000
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
238000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
483000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
250000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
239000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2024000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1630000
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1015000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1346000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4047000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6610000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5062000
CY2022Q4 us-gaap Inventory Net
InventoryNet
7956000
CY2022Q3 drio Aggregative Consideration
AggregativeConsideration
2650000
CY2023Q1 drio Aggregative Consideration
AggregativeConsideration
90000
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20352000
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
27656000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1320000
CY2023Q4 drio New Performance Obligations
NewPerformanceObligations
5353000
CY2023 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-5676000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
997000
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
238000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
483000
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
59000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
41000
CY2023Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
297000
CY2022Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
524000
CY2022Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
524000
CY2023 drio Deferred Costs Additions
DeferredCostsAdditions
474000
CY2023 drio Deferred Costs Decrease
DeferredCostsDecrease
701000
CY2023Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
297000
CY2023Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
30000000
CY2023Q4 drio Fair Value Adjustments Proceeds Allocated To Loan
FairValueAdjustmentsProceedsAllocatedToLoan
28215000
CY2023Q4 drio Fair Value Adjustments Proceeds Allocated To Warrants
FairValueAdjustmentsProceedsAllocatedToWarrants
1389000
CY2022 drio Initial Commitment Amount Remeasurement Income
InitialCommitmentAmountRemeasurementIncome
187000
CY2023 drio Initial Commitment Amount Remeasurement Income
InitialCommitmentAmountRemeasurementIncome
187000
CY2022Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
CY2022Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
50000000
CY2022Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000000
CY2022Q2 drio Line Of Credit Amount Available Subject To Revenue Requirements
LineOfCreditAmountAvailableSubjectToRevenueRequirements
25000000
CY2023Q2 drio Line Of Credit Discretionary Tranche
LineOfCreditDiscretionaryTranche
10000000
CY2023Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
30000000
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1413000
CY2023Q4 us-gaap Debt Instrument Measurement Input
DebtInstrumentMeasurementInput
0.19
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
392000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
278000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
10000
CY2023 us-gaap Lease Cost
LeaseCost
680000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M13D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0938
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
124000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
305000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
279000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
279000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
284000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1271000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
275000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
996000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
328000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
136000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2388000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2227000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1489000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1439000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
899000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
788000
CY2022 us-gaap Depreciation
Depreciation
356000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
17312000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
17312000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11908000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7396000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5404000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9916000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4512000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4361000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4452000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
952000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5404000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4073000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4407000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2227000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2185000
CY2023Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6300000
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6592000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.23
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.23
CY2023 drio Operating Loss Carryforwards Subject To Expiration
OperatingLossCarryforwardsSubjectToExpiration
36786000
CY2023 drio Operating Loss Carryforwards Not Subject To Expiration
OperatingLossCarryforwardsNotSubjectToExpiration
7120000
CY2023 drio Remaining Net Operating Losses
RemainingNetOperatingLosses
29666000
CY2023Q4 drio Percentage Of Income To Be Offset By Net Operating Loss Carry Forwards
PercentageOfIncomeToBeOffsetByNetOperatingLossCarryForwards
0.80
CY2023 drio Percentage Of Future Net Income That Can Be Offset By Net Operating Loss Carryforwards Under Cares Act
PercentageOfFutureNetIncomeThatCanBeOffsetByNetOperatingLossCarryforwardsUnderCaresAct
1
CY2023Q4 drio Deferred Tax Assets Operating Loss Carryforwards And Capital Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndCapitalLossCarryforwards
51533000
CY2022Q4 drio Deferred Tax Assets Operating Loss Carryforwards And Capital Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndCapitalLossCarryforwards
45790000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3815000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4058000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
370000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
366000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4328000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3734000
CY2022Q4 drio Deferred Tax Assets Tax Credit Facility
DeferredTaxAssetsTaxCreditFacility
723000
CY2023Q4 drio Deferred Tax Assets Loan
DeferredTaxAssetsLoan
306000
CY2023Q4 drio Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
152000
CY2022Q4 drio Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
65000
CY2023Q4 drio Deferred Tax Assets Lease
DeferredTaxAssetsLease
229000
CY2022Q4 drio Deferred Tax Assets Lease
DeferredTaxAssetsLease
253000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
60733000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54989000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
58303000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
52504000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2430000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2485000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2208000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2208000
CY2023Q4 drio Deferred Tax Liabilities Leaes
DeferredTaxLiabilitiesLeaes
222000
CY2022Q4 drio Deferred Tax Liabilities Leaes
DeferredTaxLiabilitiesLeaes
277000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2430000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2485000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5798000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23477000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-22902000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-35886000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-39287000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59363000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62189000
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
21375
CY2019Q4 drio Gross Proceeds From Issuance Of Preferred Stock And Preference Stock
GrossProceedsFromIssuanceOfPreferredStockAndPreferenceStock
21375000
CY2019Q4 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18689000
CY2019Q4 drio Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
2860000
CY2022Q3 drio Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
62000
CY2023Q2 drio Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
984000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2528890
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3160430
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2124302
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.38
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M23D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
121000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1213900
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.33
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6821
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
221313
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
30.51
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
559239
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.86
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2550829
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.27
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2089935
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.61
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M17D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
36000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1326486
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.45
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M20D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
36000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.14
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.43
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9407000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y9M25D
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19701000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16975000
CY2023 drio Bank Charges
BankCharges
112000
CY2022 drio Bank Charges
BankCharges
83000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-210000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
243000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
1868000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
506000
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
37000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
1876000
CY2023 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
4894000
CY2022 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
3858000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-670000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1020000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
533000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
724000
CY2023 drio Liabilities Fair Value Adjustment Credit Agreement
LiabilitiesFairValueAdjustmentCreditAgreement
0
CY2022 drio Liabilities Fair Value Adjustment Credit Agreement
LiabilitiesFairValueAdjustmentCreditAgreement
-607000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3174000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5379000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12188189
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5744428

Files In Submission

Name View Source Status
0001558370-24-004151-index-headers.html Edgar Link pending
0001558370-24-004151-index.html Edgar Link pending
0001558370-24-004151.txt Edgar Link pending
0001558370-24-004151-xbrl.zip Edgar Link pending
drio-20231231.xsd Edgar Link pending
drio-20231231x10k.htm Edgar Link pending
drio-20231231x10k001.jpg Edgar Link pending
drio-20231231x10k002.jpg Edgar Link pending
drio-20231231x10k003.jpg Edgar Link pending
drio-20231231x10k011.jpg Edgar Link pending
drio-20231231xex10d23.htm Edgar Link pending
drio-20231231xex10d24.htm Edgar Link pending
drio-20231231xex10d34.htm Edgar Link pending
drio-20231231xex10d35.htm Edgar Link pending
drio-20231231xex10d35001.jpg Edgar Link pending
drio-20231231xex21d1.htm Edgar Link pending
drio-20231231xex23d1.htm Edgar Link pending
drio-20231231xex31d1.htm Edgar Link pending
drio-20231231xex31d2.htm Edgar Link pending
drio-20231231xex32d1.htm Edgar Link pending
drio-20231231xex97d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
drio-20231231_def.xml Edgar Link unprocessable
drio-20231231x10k_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
drio-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drio-20231231_cal.xml Edgar Link unprocessable
drio-20231231_pre.xml Edgar Link unprocessable